Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women.
Frequent mood and sleep disorders and increased appetite leading to obesity are observed in postmenopausal women . Due to the limitations of hormone replacement therapy the research ers look for other treatment regimes . The aim of the study was to evaluate the efficacy of fluoxetine and melatonin in the treatment of these disorders . The study included 64 overweight postmenopausal women , aged 54 - 65 years , with increased appetite . They were r and omly assigned in 2 groups . In group I ( n = 30 ) fluoxetine ( 20 mg in the morning ) and placebo ( in the evening ) were administered for 24 weeks . Group II ( n = 34 ) received fluoxetine ( 20 mg in the morning ) and melatonin ( 5 mg in the evening ) in the same period of time . Hamilton anxiety rating scale ( HARS ) , Beck depression scale ( BDI ) , the insomnia severity index ( ISI ) and body mass index ( BMI ) were used to assess the health status and the treatment efficacy . After 24 weeks , comparable and statistically significant reduction in the level of anxiety and depression was obtained in both groups . In group I , the ISI decreased from 14.9 ± 2.5 points to 10.9 ± 1.9 points ( P < 0.05 ) and in group II from 15.8 ± 2.4 points to 7.7 ± 1.5 points ( P < 0.001 ) . In group I no reduction in BMI was achieved whereas in group II this index decreased from 30.9 ± 3.1 to 26.3 ± 3.2 ( P < 0.05 ) . We conclude that combined administration of fluoxetine and melatonin was useful option to treat mood , sleep and appetite disorders in postmenopausal women
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .